We found that the samples from Stage 1 patients exhibited varying levels of S100A8/A9, as did those from Stage 3 and 4 patients, with some samples exceeding 5.5 μg/mL (Fig. 5f), a level associated with poor responses to anti-PD-1 therapy in a recent melanoma study17. This evidence concerns the gene S100A8 and melanoma.